Investigation of microglial involvement in the effect of intranasal oxytocin on social behavior.
- Conditions
- none
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 24
(1) Males between the ages of 18 and 55 at the time consent is obtained (2) Total intelligence quotient > 80 (3) Individuals who have given their written consent to participate in this study
(1) Has been diagnosed with a mental illness (2) Use of psychotropic drugs in the past 6 months (3) History of hypersensitivity to oxytocin (4) History of epileptic seizures or head trauma with loss of consciousness for more than 5 minutes (5) History of alcohol-related or other substance-related disorders (6) Taking anti-inflammatory medications, which cannot be discontinued from one month prior to study drug administration (Visit 1) until Visit 2 or the end of the study (7) Has a family history of male breast cancer (8) Patients with a serious medical condition (9) Have a drug allergy, food allergy, or a specific constitution (10) Who cannot give consent to use contraception during the study period (11) Participate in any other research or clinical research (except for research involving PET imaging using [11C]DPA713) and receive any medication within 120 days prior to obtaining consent (12) Other subjects deemed ineligible for this study by the Principal Investigator(s).
Study & Design
- Study Type
- Interventional
- Study Design
- crossover assignment
- Primary Outcome Measures
Name Time Method - PET measurement: Binding potential (BP)ND of [11C]DPA713
- Secondary Outcome Measures
Name Time Method Number of friend / foe judgments Number of friend / foe judgments based on nonverbal information during Verbal Non-verbal Test (VnV)
Reaction time Reaction time during Verbal Non-verbal Test (VnV)
Gazing time on eye region Gazing time on eye region during Verbal Non-verbal Test (VnV)